Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse
about
Duchenne Muscular Dystrophy: From Diagnosis to TherapyHuman skeletal muscle xenograft as a new preclinical model for muscle disordersLong-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophySelective modulation through the glucocorticoid receptor ameliorates muscle pathology in mdx miceFluoxetine prevents dystrophic changes in a zebrafish model of Duchenne muscular dystrophy.Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trialsAsynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.The effects of glucocorticoid and voluntary exercise treatment on the development of thoracolumbar kyphosis in dystrophin-deficient mice.VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.A reporter mouse for optical imaging of inflammation in mdx musclesGenetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy.Behavioral and locomotor measurements using an open field activity monitoring system for skeletal muscle diseases.The Angiotensin Converting Enzyme Inhibitor Lisinopril Improves Muscle Histopathology but not Contractile Function in a Mouse Model of Duchenne Muscular Dystrophy.Levels of α7 integrin and laminin-α2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy.Molecular Signatures of Membrane Protein Complexes Underlying Muscular Dystrophy.Similar efficacy from specific and non-specific mineralocorticoid receptor antagonist treatment of muscular dystrophy mice.Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model.What has the mdx mouse model of Duchenne muscular dystrophy contributed to our understanding of this disease?Intermittent Glucocorticoid Dosing Improves Muscle Repair and Function in Mice with Limb Girdle Muscular Dystrophy.Gene expression effects of glucocorticoid and mineralocorticoid receptor agonists and antagonists on normal human skeletal muscle.Long-term dietary quercetin enrichment as a cardioprotective countermeasure in mdx mice.Renin-angiotensin-aldosterone system inhibitors improve membrane stability and change gene-expression profiles in dystrophic skeletal muscles.Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy.Functional improvement of dystrophic muscle by repression of utrophin: let-7c interaction.Glucocorticoids Improve Myogenic Differentiation In Vitro by Suppressing the Synthesis of Versican, a Transitional Matrix Protein Overexpressed in Dystrophic Skeletal Muscles.Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy.RhoA/ROCK inhibition improves the beneficial effects of glucocorticoid treatment in dystrophic muscle: implications for stem cell depletion.Impact of Inflammation and Anti-inflammatory Modalities on Skeletal Muscle Healing: From Fundamental Research to the Clinic.
P2860
Q26784259-6E916783-6571-4C8B-B671-289FA3CF35E5Q33649287-9A618518-77E8-4FBA-A346-21135E6AEB44Q33649312-C4D72123-6551-48CF-95A1-6E987C83AEBEQ33925571-84CBB32E-60D9-4D86-9D38-4E7C0D8DF22EQ33991780-0E2E2A80-F7F8-4165-BFF7-487E875E8FCDQ34152280-8B3DCDB0-A2FB-4481-A3F9-9B8A30751C8AQ34332718-7AE168E8-B2EC-46F1-BBC6-94E17A172089Q34474684-5AD8491C-BB47-4C57-A907-9BD1D65E751BQ34981147-23495E24-F18B-49B1-ACC1-FF051F4A8897Q35097376-1582B132-E3B8-4B35-99FB-91112E43A429Q35576368-7B690646-278E-487B-AACE-19E8A63DA7CBQ35826211-26CC45DF-5F47-4E68-AE58-2792435BCCDCQ36355247-528C10BF-939D-4245-B0FB-7E5E1904E33AQ36817631-40F9A18F-9E6F-4CAA-A488-F019453146EFQ37137768-E4D14A1E-B206-490D-83A5-638AF0D88F25Q37372312-210E7AC1-18F7-43CA-8637-11B124B73632Q37395745-B5B937EE-6CB0-423E-95AE-948FC76B3652Q37494390-D347B9B1-F6B6-45CF-AB2B-51DD88138CB1Q38351283-07E93886-B2A9-4B65-990D-C5F5944D5C80Q38617041-505CC512-6109-43DC-90F2-4CC2515AE298Q38825776-0CC6E233-4E3D-437B-AE92-0282DDD64370Q38963842-3CDD2305-0F01-492D-80DE-963CB624A57AQ39158020-A79681D9-C886-4ABD-9749-132A52661D22Q42234763-8635A5D7-F022-4E96-95A8-CF5A51CD89EAQ42680577-11128481-6096-4D0B-A728-DA419462764EQ47324398-6F403D0C-AC1B-4119-9FB7-EDDA9A8AD728Q47665947-242B5DDD-127B-4431-BD9B-02FEF6D45974Q50977301-86D24F02-ABD6-4D81-B566-58E312D2981CQ51811548-0E83FCE3-0932-42F9-9A6C-846A831CEC29
P2860
Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Glucocorticoid-treated mice ar ...... nical studies in the mdx mouse
@ast
Glucocorticoid-treated mice ar ...... nical studies in the mdx mouse
@en
Glucocorticoid-treated mice ar ...... nical studies in the mdx mouse
@nl
type
label
Glucocorticoid-treated mice ar ...... nical studies in the mdx mouse
@ast
Glucocorticoid-treated mice ar ...... nical studies in the mdx mouse
@en
Glucocorticoid-treated mice ar ...... nical studies in the mdx mouse
@nl
prefLabel
Glucocorticoid-treated mice ar ...... nical studies in the mdx mouse
@ast
Glucocorticoid-treated mice ar ...... nical studies in the mdx mouse
@en
Glucocorticoid-treated mice ar ...... nical studies in the mdx mouse
@nl
P2093
P2860
P3181
P1433
P1476
Glucocorticoid-treated mice ar ...... nical studies in the mdx mouse
@en
P2093
Alfredo D Guerron
Arpana Sali
Christopher F Spurney
Eric P Hoffman
Heather Gordish-Dressman
Micaela Iantorno
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0034204
P407
P577
2012-01-01T00:00:00Z